$2.24
-0.04 (-1.75%)
Open$2.21
Previous Close$2.28
Day High$2.42
Day Low$2.13
52W High$2.95
52W Low$0.74
Volume—
Avg Volume953.5K
Market Cap273.96M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+167.9% upside
Current
$2.24
$2.24
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 57.1K | 9.23M | 9.01M |
| Net Income | -96,772,329 | -678,125 | -522,642 |
| Profit Margin | -155,587.4% | -7.4% | -5.8% |
| EBITDA | -101,466,829 | -963,511 | -904,753 |
| Free Cash Flow | — | -508,030 | -465,093 |
| Rev Growth | — | +6.0% | +24.9% |
| Debt/Equity | 0.02 | 0.23 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |